Equities

Zeria Pharmaceutical Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
4559:TYO

Zeria Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)2,044.00
  • Today's Change2.00 / 0.10%
  • Shares traded10.50k
  • 1 Year change-1.49%
  • Beta0.3347
Data delayed at least 15 minutes, as of Jul 07 2025 05:41 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Zeria Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the development of ethical drug business, consumer healthcare business and other business. The Company operates in two business segments. The Ethical Drug segment is engaged in the research, development, manufacture and sale of ethical drugs. The Consumer Healthcare segment is engaged in the manufacture, purchase and sale of over-the-counter (OTC) drugs, health foods, quasi drugs and cosmetics related to self-medication. The others include insurance agency business and real estate business, as well as various maintenance business such as purchasing and sale of promotional materials.

  • Revenue in JPY (TTM)87.31bn
  • Net income in JPY9.94bn
  • Incorporated1955
  • Employees1.75k
  • Location
    Zeria Pharmaceutical Co Ltd10-11, Nihombashi Kobuna-choCHUO-KU 103-8351JapanJPN
  • Phone+81 336632351
  • Fax+81 336632352
  • Websitehttps://www.zeria.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Renascience Inc132.69m113.43m23.99bn3.00211.4713.94183.90180.778.928.9210.44135.320.067--11.9544,231,000.005.73-8.976.16-9.3597.1884.4485.48-107.53---588.250.00---31.6613.00143.91------
Daito Pharmaceutical Co Ltd48.84bn2.17bn30.52bn1.07k14.330.5964.870.624870.7570.751,594.281,701.230.63441.902.9745,646,730.002.606.273.348.2418.2622.654.098.471.30--0.168919.593.982.66-8.47-1.2711.3711.67
Fuji Pharma Co Ltd48.85bn3.18bn33.37bn1.66k10.280.71694.680.6831130.56130.562,006.721,872.090.54981.353.3729,460,190.003.584.645.516.6339.9241.296.518.830.828224.960.414526.1412.844.9378.9215.725.897.94
Seikagaku Corp39.37bn1.21bn35.51bn1.08k28.080.466111.060.901822.2522.25721.501,340.970.47532.075.1536,626,980.001.473.601.613.9648.6452.563.097.943.73--0.005255.178.736.57-44.46--18.482.90
Cuorips Inc175.21m-644.34m46.25bn56.00--8.35--263.98-80.64-80.6421.89682.900.02940.2992.193,128,661.00-10.82---11.15--96.03---368.32--28.65-17.490.00--658.40---1.92------
JCR Pharmaceuticals Co Ltd33.07bn-4.76bn68.73bn987.00--1.37--2.08-38.86-38.86267.09386.120.31940.53092.4333,507,600.00-4.545.86-7.109.3365.7373.83-14.2013.600.666-26.060.446645.13-22.865.94-186.42--15.3720.11
ASKA Pharmaceutical Holdings Co Ltd64.14bn5.10bn70.73bn1.63k13.671.079.631.10179.94179.942,262.572,302.590.67061.404.1839,300,860.005.335.507.267.0748.8647.567.957.981.39--0.136116.602.064.07-32.3951.049.4931.48
Nxera Pharma Co Ltd30.87bn-2.32bn79.28bn374.00--1.1744.892.57-25.83-25.83343.68746.050.20721.486.9682,534,760.00-1.56-1.71-1.72-1.8573.9584.07-7.51-10.933.11--0.497--125.8724.2832.74--40.57--
Katakura Industries Co Ltd40.12bn3.92bn84.69bn941.0019.950.911512.172.11120.54120.541,233.122,638.590.28852.324.7642,634,430.002.972.603.663.5737.0137.9810.299.442.55--0.094723.42-1.37-2.1915.7315.27-7.2233.03
Kyorin Pharmaceutical Co Ltd130.09bn9.09bn89.32bn2.00k9.420.62816.520.6866158.16158.162,264.402,372.280.70081.182.7865,108,610.004.893.346.254.1645.7745.896.985.112.01--0.172757.348.833.4170.738.1214.36-7.06
Mochida Pharmaceutical Co Ltd105.16bn5.69bn105.57bn1.51k18.090.786912.241.00160.36160.362,966.323,686.670.65951.623.1669,734,090.003.574.504.245.4451.1552.495.416.873.4740.430.002643.012.210.651625.034.341.980.00
Zeria Pharmaceutical Co Ltd87.31bn9.94bn108.47bn1.75k9.061.016.191.24225.42225.421,980.762,031.330.56381.513.7050,006,380.006.444.679.957.4773.2572.1711.429.020.9752--0.320928.7515.307.6428.5227.7116.516.69
Towa Pharmaceutical Co Ltd259.59bn18.99bn151.15bn4.79k7.610.84163.870.5823385.70385.705,273.633,486.390.57591.573.6954,217,630.004.213.895.185.0736.4937.817.316.611.58--0.573721.5213.8918.6517.395.5346.239.73
Data as of Jul 07 2025. Currency figures normalised to Zeria Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

8.38%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 May 20251.25m2.35%
Nomura Asset Management Co., Ltd.as of 05 Jun 2025984.60k1.85%
Nikko Asset Management Co., Ltd.as of 06 Jun 2025461.20k0.87%
Daiwa Asset Management Co. Ltd.as of 30 May 2025442.50k0.83%
Dimensional Fund Advisors LPas of 05 Jun 2025292.90k0.55%
Norges Bank Investment Managementas of 31 Dec 2024286.87k0.54%
BlackRock Japan Co. Ltd.as of 05 Jun 2025259.60k0.49%
Mitsubishi UFJ Asset Management Co., Ltd.as of 05 Jun 2025190.00k0.36%
BlackRock Fund Advisorsas of 05 Jun 2025146.70k0.28%
Mellon Investments Corp.as of 06 Jun 2025136.70k0.26%
More ▼
Data from 31 Dec 2024 - 31 Mar 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.